Viewing Study NCT00002749



Ignite Creation Date: 2024-05-05 @ 9:57 AM
Last Modification Date: 2024-10-26 @ 9:03 AM
Study NCT ID: NCT00002749
Status: COMPLETED
Last Update Posted: 2009-10-14
First Post: 1999-11-01

Brief Title: Carboplatin in Patients With Progressive Gliomas
Sponsor: Duke University
Organization: Duke University

Study Overview

Official Title: PHASE II STUDY OF CARBOPLATIN CBDCA IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS
Status: COMPLETED
Status Verified Date: 2009-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

PURPOSE Phase II trial to study the effectiveness of carboplatin in patients with progressive glioma
Detailed Description: OBJECTIVES I Assess the response to carboplatin CBDCA in patients with progressive low-grade gliomas II Assess the activity of CBDCA in stabilizing the growth of these tumors

OUTLINE Single-Agent Chemotherapy Carboplatin CBDCA NSC-241240

PROJECTED ACCRUAL A total of 25 evaluable patients will be entered if there is at least 1 response in the first 9 patients

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
NCI-V96-0868 None None None
DUMC-0157-00-1R7 None None None
DUMC-0137-99-1R6 None None None
DUMC-081-96-1R3 None None None
DUMC-115-97-1R4 None None None
DUMC-118-98-1R5 None None None